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2		
Abstract		
Background		Pneumococcal	infections	are	major	causes	of	morbidity	and	mortality	worldwide.	We	use	 routine	hospital	 admissions	data	 and	 time-series	modelling	analysis	 to	estimate	 the	 impact	 of	 the	 seven	 and	 thirteen	 valent	 pneumococcal	 conjugate	vaccines	(PCV7	and	PCV13)	on	hospital	admissions	due	to	pneumococcal	disease	in	England.			
Methods		Hospital	admissions	 for	pneumococcal	meningitis,	bacteraemia	and	pneumonia	between	 January	 1,	 2003	 and	 December	 31,	 2015	 were	 identified	 from	 the	national	Hospital	Episode	Statistics	database	 for	all	 age	groups	 in	England.	We	model	 the	 impact	 of	 pneumococcal	 vaccination	 using	 interrupted	 time	 series	analysis.	Hospital	admissions	prior	to	vaccine	introduction	were	extrapolated	to	predict	 the	 expected	 number	 of	 admissions	 in	 the	 absence	 of	 pneumococcal	vaccines.	Admissions	avoided	over	time	were	estimated	by	comparing	the	fitted	interrupted	time	series	and	the	expected	model	for	no	vaccination	in	a	Bayesian	framework.			
Results		Overall,	there	were	43	531	(95%	credible	interval	(CrI):	36	486	–	51	346)	fewer	hospital	 admissions	due	 to	bacteraemia,	meningitis	 and	pneumonia	 in	England	during	 the	 period	 from	 2006	 to	 2015	 than	 would	 have	 been	 expected	 if	pneumococcal	vaccines	had	not	been	implemented,	with	the	majority	of	hospital	admissions	 avoided	 due	 to	 pneumonia.	 Among	 young	 children	 reductions	 in	meningitis	 were	more	 common,	 while	 among	 adults	 reductions	 in	 pneumonia	admissions	 were	 relatively	 more	 important,	 with	 no	 evidence	 for	 reduced	bacteraemia	and	meningitis	among	older	adults.	We	estimated	that	981	(95%	CrI:	391	 –	 2	 018),	 749	 (95%	CrI:	 295	 –	 1	 442)	 and	1	 464	 (95%	CrI:	 793	 –	 2	 522)	bacteraemia,	meningitis	and	pneumonia	related	hospital	admissions,	respectively,	were	averted	in	children	<2	years	of	age.		
Conclusions		Substantial	 reductions	 in	 hospital	 admissions	 for	 bacteraemia,	 meningitis	 and	pneumonia	 in	 England	 were	 estimated	 after	 the	 introduction	 of	 childhood	vaccination,	 with	 indirect	 effects	 being	 responsible	 for	 most	 of	 the	 hospital	admissions	avoided.		
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Background		Pneumococcal	infections	are	a	major	cause	of	long-term	morbidity	and	mortality	(1-3).	 The	 introduction	 of	 childhood	pneumococcal	 vaccination	has	 resulted	 in	significant	 reductions	 in	 pneumococcal	 disease	 in	 both	 vaccinated	 and	unvaccinated	individuals	worldwide.	Surveillance	programmes	on	pneumococcal	disease	have	shown	that	invasive	pneumococcal	disease	due	to	serotypes	covered	by	the	vaccine	have	continued	to	decline	following	vaccine	introduction	(4-10).	However,	 the	 vaccine	 programme	 has	 also	 been	 associated	 with	 concomitant	increases	 in	 carriage	 and	 disease	 due	 to	 other	 serotypes	 not	 contained	 in	 the	vaccine	(11-13).	There	are	concerns	that	serotype	replacement	could	erode	the	benefits	of	the	pneumococcal	vaccine	in	the	long	term.		England	and	Wales	introduced	the	seven-valent	conjugate	vaccine	(PCV7;	containing	serotypes	4,	6B,	9V,	14,	18C,	19F	and	23F)	in	September	2006	as	part	of	their	universal	paediatric	immunisation	programme,	using	a	primary	series	of	two	doses	at	2	and	4	months	and	a	booster	dose	after	the	first	birthday.	During	the	first	year	of	the	programme,	a	catch-up	campaign	targeting	children	under	two	years	was	also	implemented.	In	April	2010,	PCV7	was	replaced	by	a	thirteen-valent	vaccine	(PCV13;	containing	the	seven	serotypes	contained	in	PCV7	plus	additional	six	serotypes	1,	3,	5,	6A,	7F	and	19A)	in	the	childhood	vaccination	programme.		Vaccination	coverage	for	the	primary	series	and	booster	dose	has	risen	from	80%	and	83%	in	the	first	year	of	vaccine	introduction	to	90%	and	94%	in	2015/16,	respectively	(11,	12,	14).	Adults	aged	65	years	and	at-risk	groups	aged	two	years	or	over	are	typically	given	the	polysaccharide	pneumococcal	vaccine	(PPV23;	containing	serotypes	1,	2,	3,	4,	5,	6B,	7F,	8,	9N,	9V,	10A,	11A,	12F,	14,	15B,	17F,	18C,	19A,	19F,	20,	22F,	23F,	and	33F).	PPV23	immunisation	in	adults	was	introduced	in	August	2003.	During	the	first	year,	all	people	³80	years	were	eligible	for	a	single	dose	and	in	April	2004	it	was	extended	to	cover	people	aged	³75	years.	In	April	2005,	a	universal	PPV23	schedule	for	adults	aged	³65	years	was	introduced	and	coverage	in	this	age	group	has	remained	stable	at	around	70%	since	introduction	(15).	PCV	is	not	available	for	adults	in	England	and	Wales	apart	from	the	severely	immunocompromised.				Although	studies	using	laboratory-based	surveillance	data	have	shown	sustained	decreases	in	invasive	pneumococcal	disease	for	the	whole	population	in	England	and	Wales	since	the	introduction	of	childhood	vaccination	programmes	(11,	12),	the	use	of	microbiologically	confirmed	cases	might	under	estimate	the	burden	of	disease	as	they	focus	on	invasive	disease	confirmed	by	culture	from	sterile	sites	and	not	on	culture	negative	pneumonia.	There	 is	 limited	data	on	 the	 impact	of	vaccination	 on	 long-term	 trends	 in	 hospital	 admissions	 following	 vaccine	introduction	 for	 individual	pneumococcal	disease	 infections	(16,	17).	 Improved	knowledge	 of	 disease	 burden	 is	 critical	 to	 inform	 future	 research	 and	 guide	intervention	policy	(18-20).	We	assessed	the	impact	of	pneumococcal	vaccination	on	 individual	 and	 composite	 pneumococcal	 disease	 hospitalisation	 in	 England	from	2003	to	2015	using	interrupted	time	series	analysis.			
4		
Methods	
	
Datasets	Data	was	extracted	 from	 the	Hospital	Episode	Statistics	 (HES)	database,	which	contains	 information	 on	 all	 acute	 care	 hospitalisations	 in	 England.	 Datasets	analysed	comprised	of	all	inpatient	hospitalisations	between	January	1,	2003	and	December	31,	2015.	Cases	were	identified	by	the	presence	of	relevant	diagnostic	discharge	codes	(primary	or	secondary	diagnosis)	listed	in	the	patient’s	discharge	record.	 The	 discrete	 health	 states	 or	 medical	 conditions	 associated	 with	
Streptococcus	 pneumoniae	 infection	 identified	were	 bacteraemia	 (International	Classification	of	Diseases,	10th	revision	[ICD-10],	code	A403),	meningitis	(G001)	and	pneumonia	with	or	without	a	positive	culture	 from	a	sterile	site	(J13).	Our	data	 represents	 more	 severe	 cases	 of	 pneumococcal	 infections	 requiring	hospitalisation.			The	number	of	 inpatient	hospitalisations	attributed	to	pneumococcal	 infections	were	aggregated	by	month	and	stratified	according	to	the	following	age	groups:	<2	years,	2-4	years,	5-14	years,	15-44	years,	45-64	years,	and	≥65	years.	Although	all	 hospital	 episodes	 for	 each	 patient	 were	 obtained,	 we	 only	 used	 the	 first	admission	episode	that	was	due	to	a	pneumococcal	infection	for	each	patient	in	any	epidemiological	year.	The	period	January	2003	to	March	2007	was	defined	as	the	pre-PCV7	period,	April	2007	to	October	2010	as	the	PCV7-era	or	pre-PCV13	period	and	November	2010	onwards	as	the	post-PCV13	period.	Data	on	mid-year	and	age-specific	national	population	estimates	from	2003	to	2015	was	obtained	from	the	Office	for	National	Statistics,	the	national	statistical	institute	of	the	United	Kingdom.		
Statistical	analysis			For	each	disease	category,	we	ran	age-specific	Poisson	regression	models	with	and	without	vaccination	on	monthly	time	series.	We	fitted	segmented	Poisson	models	using	 a	 Bayesian	 framework.	Uncertainty	was	 given	 by	 95%	 credible	 intervals	(CrIs)	 obtained	 using	 the	 parameter	 posterior	 distributions.	We	 compared	 the	regression	models	without	the	impact	of	vaccination	with	those	with	the	impact	of	vaccination	(i.e.,	the	interrupted	time	series	regression)	to	test	whether	there	was	 a	 change	 over	 time	 and	 step	 change	 of	 hospital	 admissions	 after	 vaccine	introduction	(see	Supplementary	Appendix).	In	the	interrupted	time	series	model,	we	created	an	indicator	variable	taking	the	value	1	for	the	PCV7	era	and	0	for	both	the	 pre-PCV7	 and	 the	 period	 after	 switching	 PCV7	 with	 PCV13.	 The	 second	indicator	variable	captured	the	pre-PCV13	and	post-PCV13	periods.	The	expected	trend	in	the	absence	of	any	vaccination	(the	counterfactual)	was	based	on	the	pre-PCV7	 data.	 Cases	 (hospital	 admissions)	 averted	 over	 time	 were	 calculated	 by	comparing	 the	 fitted	 interrupted	 time	series	and	 the	 counterfactual	model.	We	used	the	results	of	these	calculations	to	estimate	cumulative	reductions	in	hospital	admissions.		Our	pre-vaccine	data	covers	a	short	period,	and	we	extrapolated	the	pre-vaccine	trend	based	on	3	years	data	out	for	approximately	10	years.	Because	this	might	give	unreliable	estimates	we	tested	the	robustness	of	our	analysis	by	also	fitting	
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the	 counterfactual	model	 taking	up	 to	April	2010	as	baseline.	 	We	also	 fitted	a	series	 of	 regression	 models	 changing	 the	 lag	 period	 before	 any	 PCV7-vaccine	impact	is	expected.	We	varied	this	period	from	January	2007	to	October	2007.	In	addition,	as	well	as	considering	the	two	intervention	schedules,	PCV7	and	PCV13,	separately,	we	also	conducted	analyses	assuming	that	the	impact	of	PCV13	was	similar	to	that	of	PCV7.		
Results		During	the	years	studied,	January	1,	2003	to	December	31,	2015,	there	were	60	989	cases	of	patients	with	a	 first	admission	 for	any	of	 the	 three	pneumococcal	diseases	studied,	with	11	617	(19%),	6	062	(10%),	and	43	310	(71%)	cases	of	bacteraemia,	 meningitis,	 and	 pneumonia,	 respectively.	 Hospital	 admissions	showed	 seasonal	 fluctuations	with	 peaks	 occurring	 in	winter	months.	Monthly	hospitalisations	 for	 bacteraemia	 and	 meningitis	 were	 lowest	 in	 children	 2-14	years	of	age.					
Interrupted	time	series	analyses	
	In	Table	1	and	Figures	1	and	2,	we	present	observed	and	model-predicted	hospital	admissions,	and	the	number	of	hospital	admissions	avoided	by	disease	and	age	category.	 Reductions	 in	 hospitalisations	 for	 all	 studied	 pneumococcal	 diseases	combined	were	observed	in	all	age	groups.	In	children	<2	years,	2-4	years	and	5-14	years,	the	number	of	admissions	averted	during	the	study	period	were	3	001	(95%	CrI:	1	987	–	4	314),	2	026	(95%	CrI:	972	–	3	809)	and	2	302	(95%	CrI:	1	058	–	4	509),	respectively	(Table	1).	The	number	of	admissions	averted	for	adults	15-44	years,	45-64	years	and	³65	years	were	13	533	(95%	CrI:9	822	–	18	214),	13	719	 (95%	 CrI:	 9	 628	 –	 18	 556)	 and	 14	 909	 (95%	 CrI:	 10	 693	 –	 19	 564),	respectively.			When	 the	 analysis	 was	 stratified	 by	 disease,	 bacteraemia	 hospital	 admissions	averted	in	age	groups	<2	years,	15-44	years	and	45-64	years	decreased	over	time	after	the	introduction	of	PCV7	(Table	1;	Figures	S1,	S2	and	S3	showing	monthly	trends,	risk	rate	ratios	and	number	of	admissions	averted,	respectively).	In	these	age	groups,	the	total	number	of	admissions	averted	over	the	study	period	were	981	(95%	CrI:	391	–	2	018),	1	011	(95%	CrI:	212	–	2	374)	and	2	102	(95%	CrI:	854	 –	 4	 232),	 respectively.	 In	 other	 age	 groups,	 no	 significant	 changes	 were	observed	in	the	number	of	hospital	admissions	due	to	bacteraemia.		A	substantial	number	of	meningitis-related	hospital	admissions	were	averted	in	children	<15	years,	although	in	children	2-15	years	significant	reductions	were	only	observed	after	switching	PCV7	with	PCV13	vaccine.		An	estimated	total	of	749	(95%	CrI:	295	-	1	442),	379	(95%	CrI:	45	–	1	526),	368	(95%	CrI:	19	–	1	492)	and	560	(95%	CrI:	12	–	1	625)	admissions	were	averted	in	children	<2	years,	2-4	years,	5-14	years	and	young	adults	15-45	years,	respectively	(Table	1;	Figures	S4,	S5	and	S6,	showing	monthly	trends,	risk	rate	ratios	and	number	of	admissions	averted,	respectively).	 There	were	 no	 significant	 changes	 in	 the	 number	 of	meningitis-related	hospital	admissions	in	older	adults	³45	years	of	age.	
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	In	all	age	groups,	the	number	of	pneumonia-related	hospital	admissions	averted	was	substantial	and	sustained	over	time.	(Table	1;	Figures	S7,	S8	and	S9	showing	monthly	trends,	risk	rate	ratios	and	number	of	admissions	averted,	respectively).	These	ranged	from	1	464	(95%	CrI:	793	–	2	522)	in	children	<2	years	to	16	963	(95%	CrI:	12	662	–	21	937)	in	adults	³65	years	of	age.			Overall,	there	were	43	531	(95%	CrI:	36	486	–	51	346)	fewer	hospital	admissions	in	England	when	the	three	diseases	are	combined	over	the	period	of	study	than	would	have	been	expected	if	pneumococcal	vaccines	had	not	been	implemented	(Table	1;	Figures	S10,	S11	and	S12	showing	monthly	trends,	risk	rate	ratios	and	number	 of	 admissions	 averted,	 respectively).	 The	 large	 majority	 of	 these	reductions	(approximately	96%)	were	due	to	pneumonia	hospital	admissions	and	most	of	these	reductions	were	in	adult	populations	³15	years	of	age.		In	 a	 sensitivity	 analysis	where	we	 fitted	 the	 counterfactual	model	 taking	up	 to	October	2010	as	the	PCV7-era	and	then	switching	off	the	impact	of	the	vaccine,	we	could	 still	 reproduce	 counterfactual	 trends	 for	 no	 vaccine	 (Figure	 S13).	 In	addition,	we	observed	consistent	results	when	we	assumed	a	similar	vaccine	effect	for	PCV7	and	PCV13	(Figure	S14).			In	Figure	S15,	we	present	the	effects	of	variation	in	lag	period	before	any	vaccine	effect	is	expected	(from	January	2007	to	October	2007).	The	results	show	that	a	longer	delay	to	when	the	PCV7	effect	is	modelled	results	in	a	diminished	role	of	the	vaccination	programmes.	Overall,	our	results	were	robust	to	changes	in	the	lag	period	before	any	vaccine	is	expected	to	have	an	impact,	as	demonstrated	by	the	estimated	risk	ratios	over	time	presented	in	Figure	S16.			
Discussion	
	In	this	study,	we	have	assessed	the	impact	of	the	introduction	of	pneumococcal	conjugate	 vaccines	 in	 England	 on	 hospital	 admissions	 due	 to	 bacteraemia,	meningitis,	and	pneumonia	infections	between	January	2003	and	December	2015.	Our	estimates	suggest	that	the	childhood	pneumococcal	vaccination	programme	was	 associated	 with	 substantial	 reductions	 in	 pneumococcal	 disease-related	hospitalisations	in	all	age	groups,	with	indirect	effects	being	responsible	for	most	of	 the	 hospital	 admissions	 avoided.	 When	 stratified	 by	 disease	 condition,	 we	observed	 a	 clear	 impact	 of	 vaccines	 in	 young	 children	 <2	 years	 for	 all	pneumococcal	 infections.	 Non-significant	 reductions	 were	 observed	 for	bacteraemia	associated	hospital	admissions	in	children	2-4	years	and	5-14	years	of	age.		In	the	elderly	³65	years	of	age,	the	vaccine	indirect	impact	was	diminished	-	 with	 a	 trend	 towards	 an	 increase	 in	 bacteraemia	 hospitalisations.	 The	 small	number	of	admissions	observed	in	this	age	group	might	have	limited	our	power	to	detect	relatively	small	changes	in	the	number	of	hospital	admissions.		There	 was	 a	 sustained	 and	 substantial	 reduction	 in	 the	 number	 of	 hospital	admissions	due	to	meningitis	in	children	<15	years	of	age	and	young	adults	15-44	years	of	age,	whereas	in	older	adults	³65	years	of	age,	there	were	no	significant	
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changes	 in	the	number	of	meningitis-related	hospital	admissions.	These	results	are	similar	to	those	found	in	an	analysis	of	hospital	admissions	data	from	1999	to	2011	 (21).	 In	 children	 aged	 2-4	 years	 and	 5-14	 years,	 the	 number	 of	 hospital	admissions	due	to	meningitis	did	not	change	significantly	after	the	introduction	of	PCV7	into	the	childhood	immunisation	programme.	Plots	of	rate	ratios	over	time	before	and	after	pneumococcal	vaccines	show	a	pattern	of	decline	after	PCV7	was	replaced	with	PCV13	in	2010,	similar	to	what	has	been	observed	using	laboratory-based	surveillance	data	(22).	These	results	mirror	laboratory-based	surveillance	data	 from	 other	 settings	 where	 there	 was	 a	 marked	 decline	 in	 pneumococcal	meningitis	among	children	<2	years	and	no	significant	change	in	older	age	groups	(7,	23,	24).			Our	 results	 indicate	 that	 pneumococcal	 conjugate	 vaccines	 have	 prevented	hospital	admissions	due	to	pneumonia,	under	which	both	invasive	pneumococcal	disease	and	non-invasive	disease	were	recorded,	 in	all	age	groups	with	90%	of	reductions	 in	 individuals	³15	years	of	age	occurring	 through	herd	 immunity.	A	broadly	 similar	 90%	 reduction	 in	 pneumonia-related	 hospital	 admissions	 was	observed	 in	 adults	 in	 the	 United	 States	 (25).	 Despite	 these	 huge	 reductions,	 a	substantial	burden	of	pneumonia	remains,	particularly	in	adult	age	groups.			It	has	been	demonstrated	that	pneumococcal	vaccines	have	substantially	reduced	invasive	pneumococcal	disease	in	the	whole	population	of	England	and	Wales.	Our	data	 extend	 these	 observations	 to	 show	 significant	 reductions	 in	 hospital	admissions	 in	all	age	groups,	as	a	result	of	clinically-diagnosed	pneumonia	that	comprised	 the	 largest	 quantitative	 reduction	 in	 admissions.	 The	 patterns	 of	decline	in	all	hospitalisations	due	to	the	combined	three	pneumococcal	diseases	reflect	those	observed	from	the	surveillance	data	based	on	laboratory	confirmed	IPD	cases	over	the	same	period	(11,	12,	14).	 Including	the	 latest	data	up	to	the	epidemiological	year	2016/17,	Ladhani	et	al	estimated	that	paediatric	vaccination	approximately	saved	40	000	cases	of	 invasive	pneumococcal	disease	(12).	This	number	is	lower,	although	not	significantly	so,	than	our	estimate	of	43	531	(95%	CrI:	36	486	–	51	346),	despite	the	surveillance	data	having	more	data	points	from	an	extra	year	and	more	data	from	Wales.	Using	HES	data,	we	were	able	to	conduct	our	 estimation	 for	 individual	 disease	 outcomes,	 and	 further	 include	 combined	disease	outcomes.			Our	 study,	 using	 available	 national	 hospital	 data,	 does	 not	 cover	 recent	 years	where	preliminary	laboratory	surveillance	data	suggests	significant	replacement	disease	due	to	non-vaccine	serotypes,	particularly	in	adults.	The	recent	increase	in	 replacement	disease	 therefore	warrants	 further	work	using	 the	methods	we	have	used	here	as	sufficient	later	data	becomes	available.	Previous	studies	have	shown	an	increase	in	admissions	to	hospital	for	pneumococcal	disease	before	the	introduction	of	pneumococcal	vaccines	(17,	21,	26).	In	the	Oxfordshire	region	of	England,	 community	acquired	pneumonia	hospitalisations	 from	all	 causes	have	been	 increasing,	 with	 no	 evidence	 that	 this	 increase	 is	 influenced	 by	 coding	practices	or	 changes	 in	population	demographics	 (16).	The	 rise	may	be	due	 to	population	 factors,	 changes	 in	health	 care	organisation,	biologic	processes	or	a	combination	 of	 these	 factors	 (17).	 Given	 this	 background,	 in	 the	 absence	 of	
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vaccines,	 hospitalisations	 due	 to	 pneumococcal	 diseases	 studied	 here	 are	expected	to	have	increased,	as	shown	by	our	counterfactual	trends.			Our	study	has	several	limitations.	First,	we	did	not	have	serotype-specific	data,	so	the	 analysis	 could	not	 separate	 reductions	due	 to	 vaccine	 serotypes	 from	non-vaccine	serotype	disease.	Second,	we	have	relied	on	administrative	data	 that	 is	based	on	diagnostic	codes,	which	we	have	assumed	were	assigned	correctly;	this	may	not	always	be	the	case	as	there	may	be	miscoding.	Third,	we	did	not	attempt	to	 infer	 the	number	of	hospital	admissions	avoided	due	 to	 the	use	of	PPV23	 in	adults.	However,	 the	greatest	 reduction	 in	burden	was	among	adults	under	65	years,	rather	than	the	age	group	receiving	PPV23	routinely,	so	that	the	effect	of	PPV23	may	have	been	small.	Lastly,	the	interrupted	time	series	used	assumes	that	the	pre-vaccination	trends	are	linear	and	continue	to	be	linear	in	the	post	vaccine	period,	 thus	 missing	 unexpected	 effects	 that	 might	 affect	 the	 number	 of	hospitalisations	 observed.	 We	 also	 did	 not	 have	 data	 on	 non-pneumonia	hospitalisations	that	could	have	been	useful	to	capture	counterfactual	trends	in	hospitalisations	accurately.		Despite	 these	 limitations,	our	study	covers	 the	 longest	observation	period	post	vaccine	 introduction	 of	 any	 analysis	 examining	 the	 impact	 of	 pneumococcal	vaccinations	on	hospitalisation	due	to	individual	pneumococcal	diseases	such	as	bacteraemia,	 meningitis	 and	 pneumonia	 in	 England.	 Using	 ICD-coded	 data	 we	have	 shown	 that	 vaccines	 have	 reduced	 the	 burden	 of	 pneumococcal	 disease-related	 hospital	 admissions	 in	 unvaccinated	 populations,	 particularly	 in	 young	adults,	 similar	 results	 to	 those	 of	 laboratory-based	 surveillance.	 However,	 the	burden	of	meningitis	and	bacteraemia	has	not	changed	in	adults	³65	years	of	age,	despite	this	population	receiving	PPV23	in	addition	to	indirect	effects	generated	by	the	childhood	programme.	 	There	may	be	utility	in	inferring	the	population-based	impact	of	pneumococcal	vaccines	using	health-care	data	in	countries	with	little,	 or	 no	 laboratory-based	 surveillance	 for	 pneumococcal	 disease,	 including	many	low	and	middle-income	countries.			
Conclusions	This	study	provides	additional	observational	evidence	about	temporal	trends	in	pneumococcal	disease	in	England	before	and	after	the	introduction	of	paediatric	pneumococcal	 vaccinations.	 Our	 analysis	 has	 shown	 that	 these	 vaccines	 have	significantly	 reduced	 the	 burden	 of	 pneumococcal	 disease	 related	 hospital	admissions,	 including	both	 culture	 confirmed	 and	 culture	negative	pneumonia,	with	 indirect	 effects	 being	 responsible	 for	 most	 of	 the	 hospital	 admissions	avoided.												
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Figure	legends	
	
Figure	1.	Observed	and	fitted	monthly	trends	in	all	pneumococcal	disease	-related	hospitalisations	 between	 2003	 and	 2015	 by	 age	 category.	 Vertical	 grey	 lines	represent	 the	 months	 when	 PCV7	 and	 PCV13	 were	 introduced	 into	 the	immunisation	 programme,	 respectively.	 Counterfactual	 –	 expected	 hospital	admissions	in	the	absence	of	vaccination	(blue	lines).	95%	credible	intervals	are	given	in	light	blue	lines.	
	
Figure	2.	Estimated	monthly	pneumococcal	disease	admissions	averted	due	to	the	introduction	of	the	vaccination	programmes	by	age	category.	Error	bars	represent	the	95%	credible	intervals.	Vertical	 lines	represent	the	months	when	PCV7	and	PCV13	were	introduced	into	the	immunisation	programme,	respectively.				
Additional	files	File	name:		Supplementary	Appendix		Title	of	data:		Supplementary	Appendix		Description	of	data:	This	supplementary	file	contains	detailed	statistical	approaches	used	to	analyse	the	 data,	 additional	 results	 for	 individual	 disease	 conditions	 and	 sensitivity	analysis	 exploring	 the	 impact	 of	 fitting	 different	 counterfactual	 models	 and	adjusting	the	time	when	vaccines’	effect	is	started	in	the	time	series	analysis.																
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Table	 1.	 Observed	 and	 estimated	 (in	 the	 presence	 and	 absence	 of	
vaccination)	 total	number	of	hospital	admissions	and	admissions	averted	
between	2003	and	2015,	including	95%	credible	intervalsa.		
	 Bacteraemia	 Meningitis	 Pneumonia	 All	diseases		
Age	group	 	 	 	 	
<2	years	 	 	 	 	Observed		 1	248	 1	818	 1	243	 4	309	ITSb	 1	248	(1	180,	1	318)	 1	818(1	735,	1	903)	 1	243(1	176,	1	314)	 4	308(4	181,	4	440)	Counterfactualc	 2	232	(1	632,	3	269)	 2	566(2	103,	3	265)	 2	707(2	030,	3	770)	 7	309(6	276,	8	629)	Admissions	avertedd	 -981(-2	018,	-391)	 -749	(-1	442,	-295)	 -1	464(-2	522,	-793)	 -3	001(-4	314,	-1	987)	
2-4	years	 	 	 	 	Observed		 411	 227	 861	 1	499	ITS	 411	(372,	452)	 227(198,	257)	 861(804,	920)	 1	499(1	423,	1	575)	Counterfactual	 536	(322,	1	078)	 607(268,	1	753)	 2	595(1	542,	4	740)	 3	525(2	463,	5	325)	Admissions	averted	 -126(-661,	+87)	 -379(-1	526,	-45)	 -1	734(-3	871,	-692)	 -2	026(-3	809,	-972)	
5-14	years	 	 	 	 	Observed		 290	 279	 796	 1	365	ITS	 290	(257,	324)	 279(248,	313)	 795(741,	852)	 1	365(1	294,	1	439)	Counterfactual	 703	(273,	2	321)	 647(295,	1	778)	 2	407(1	438,	4	346)	 3	667(2	414,	5	884)	Admissions	averted		 -413(-2	030,	+14)	 -368(-1	492,	-19)	 -1	611(-3	536,	-647)	 -2	302(-4	509,	-1	058)	
15-44	years	 	 	 	 	Observed		 1	546	 939	 7	481	 9	966	ITS	 1	545(1	469,	1	624)	 939(880,	1	000)	 7	480(7	312,	7	652)	 9	967(9	772,	10	163)	Counterfactual	 2	557(1	750,	3	922)	 1	499(950,	2	569)	 20	285(16	507,	25	257)	 23	497(19	788,	28	185)	Admissions	averted		 -1	011(-2	374,	-212)	 -560(-1	625,	-12)	 -12	798(-17	750,	-9	020)	 -13	533(-18	214,	-9	822)	
45-64	years	 	 	 	 	Observed		 2	620	 1	549	 10	826	 14	995	ITS	 2	619(2	521,	2	722)	 1	549(1	473,	1	626)	 10	827(10	628,	11	031)	 14	994(14	755,	15	236)	Counterfactual	 4	772(3	458,	6	866)	 1	995(1	399,	2	996)	 22	598(18	790,	27	438)	 28	712(24	596,	33	567)	Admissions	averted	 -2	102(-4	232,	-854)	 -448(-1	442,	+141)	 -11	777(-16	597,	-7	979)	 -13	719(-18	556,	-9	628)	
³65	years	 	 	 	 	Observed		 5	392	 1	199	 21	781	 6	955	ITS	 5	392(5	249,	5	538)	 1	199(1	133,	1	267)	 21	779(21	492,	22	070)	 28	371(28	040,	28	708)	Counterfactual	 4	722	(3	459,	6	866)	 1	221(836,	1	891)	 38	751(34	403,	43	763)	 43	284(39	036,	47	987)	Admissions	averted		 +20(-1	199,	+929)	 -21(-684,	+359)	 -16	963(-21	937,	-12	662)	 -14	909(-19	564,	-10	693)	
All	age	groups	 	 	 	 	Observed		 11	507	 6	011	 42	988	 60	506	ITS	 11	506(11	298,	11	718)	 6	011(5	862,	6	165)	 42	986(42	580,	43	393)	 60	502(60	024,	60	979)	Counterfactual	 15	080(13	171,	17	492)	 8	266(7	123,	9	697)	 84	821(77	680,	92	722)	 104	022(96	921,111	847)	Admissions	averted		 -3	571(-5	973,	-1	682)	 -2	258(-3	667,-1	122)	 -41	845(-49	706,-34	692)	 -43	531(-51	346,-36	486)	aFor	each	diagnosis,	separate	models	were	fitted	by	age	group	bITS	–	interrupted	time	series	-	model	the	impact	of	vaccination		cCounterfactual	–	expected	hospital	admissions	in	the	absence	of	vaccination	dAdmissions	averted	since	April	2007			
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Figure	1.	Observed	and	fitted	monthly	trends	in	all	pneumococcal	disease	-
related	hospitalisations	between	2003	and	2015	by	age	category.	Vertical	
grey	lines	represent	the	months	when	PCV7	and	PCV13	were	introduced	into	
the	immunisation	programme,	respectively.	Counterfactual	–	expected	hospital	admissions	in	the	absence	of	vaccination	(blue	lines).	95%	credible	intervals	are	given	in	light	blue	lines.				
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Figure	2.	Estimated	monthly	pneumococcal	disease	admissions	averted	due	
to	the	 introduction	of	 the	vaccination	programmes	by	age	category.	Error	
bars	 represent	 the	 95%	 credible	 intervals.	 Vertical	 lines	 represent	 the	
months	 when	 PCV7	 and	 PCV13	 were	 introduced	 into	 the	 immunisation	
programme,	respectively.			
